Corvus PharmaceuticalsCRVS
CRVS logo
Fair Value
US$27
Share price02 Apr
US$14.8944.9% undervalued intrinsic discount
Loading
1Y179.89%
7D8.37%

Multiple Trial And Dilution Risks Will Shape Future Immunology Upside Potential

Analyst Low Target compiles bearish analysts opinions to create narratives which represent one standard deviation below the consensus price target, using forecasted revenue and earnings figures, as well as the transcripts of earnings calls.

Published
02 Apr 26
Views
4
Not Invested

Fair Value vs Share Price

US$27
vs US$14.8944.9% undervalued intrinsic discount
PastFuture-54m12m2015201820212024202620272029Revenue US$11.7mEarnings US$1.7m
22.6k%
Revenue growth
14.8%
Profit margin

Recent News & Updates

No updates

Recent updates

No updates

Stay ahead on Corvus Pharmaceuticals

  • Fair value estimate changes
  • Narrative and analyst updates
  • Key company announcements

Company analysis

Flawless balance sheet with limited growth.

Market capUS$1.3b
PB5.6x
Estimated Growth69.7%
Dividend YieldN/A
Full analysis

CEO & management

Richard Miller
CEO
9.2yrs
CEO Tenure

A clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States.